Showing results (81-90 of 234) with videos related to
Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsementStephen J Freedland, R Bryan Rumble, Antonio Finelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202Arnab Chakravarti, Michelle DeSilvio, Min Zhang, et al.International Journal of Radiation Oncology, Biology, Physics|November 8, 2008
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02Seth A Rosenthal, Kyoungwha Bae, Kenneth J Pienta, et al.Journal of the National Cancer Institute|July 10, 2014
Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trialsRonald C Chen, Peter Chang, Richard J Vetter, et al.European Urology|May 26, 2015
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical ProstatectomyWilliam C Jackson, Matthew J Schipper, Skyler B Johnson, et al.Radiation Oncology (London, England)|June 12, 2012
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapyJeffrey Vainshtein, Eyad Abu-Isa, Karin B Olson, et al.Urology|December 23, 2008
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapyDonald S Kaufman, Kathryn A Winter, William U Shipley, et al.International Journal of Radiation Oncology, Biology, Physics|May 5, 2009
Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boostSiavash Jabbari, Vivian K Weinberg, Katsuto Shinohara, et al.International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation studyJeff M Michalski, Kyounghwa Bae, Mack Roach, et al.Cancer|August 16, 2012
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancerMark Shilkrut, Gregory S Merrick, P William McLaughlin, et al.Pageof 24